Portfolio news 0

hVIVO to present at the upcoming 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain

London, UK - 27 September 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business supporting product development for companies developing antivirals, vaccines and respiratory therapeutics today announced it will be presenting at the European Respiratory Society Congress being held on September 28 - October 2, 2019 at the IFEMA, Feria de Madrid, Madrid, Spain.

The first presentation will evaluate the use of lower respiratory symptoms as a key endpoint to be used in trials along with the relationships between the endpoint and clinical markers such as lung function and asthma control. The second presentation will focus on the patterns of the immune response to a viral exacerbation in asthmatics and the timing profile of white blood cells as well as nasal and blood immune biomarkers. These presentations highlight the utility of the hVIVO viral challenge model as well as help inform trial design and endpoint selection.  

Andrew Catchpole, Director, Clinical Science, commented; "We are delighted that our abstracts have been accepted for presentation at the prestigious ERS International Congress. The data summarised in the posters is encouraging and supports our belief that the challenge model is not only helpful as a proof-of-concept for the effectiveness of agents directed at the viruses, but also as proof-of-mechanism for novel products in diseases where respiratory viruses are known to induce exacerbations."

Poster discussion presentation details:

Title: A key endpoint in viral challenge models of asthma exacerbations Poster

Authors:  Michael. A. Ghebre, Alan S. Bell, Alex J. Mann

Date & Time: 29.09.2019 at 08:30 CEST

Session Category: Airway Physiology 08:30-10:30

Presenter: Alan S. Bell, Director of Translational Operations

Location: 6D

Conference Reference Number: 347

Oral presentation details:

Title: Temporal relationships of cytokines, chemokines and cellular biomarkers during Human Rhinovirus (HRV) infection in asthmatics 

Authors: Alex J Mann, Michael A Ghebre, Alan S Bell

Date & Time: 01.10.2019 at 10:15 CEST

Session Category: Blood Eosinophils and More in Airway Diseases 08:30-10:30

Presenter: Alan S. Bell, Director of Translational Operations

Location: 8A

Conference Reference Number: 3564

A copy of the presentation materials will be made available here: https://hvivo.com/news-media/scientific-papers/

 
For further information please contact:

 

hVIVO plc

Fleur Wood (EVP, Investor Relations & Communications)

+44 207 756 1300

Numis Securities Limited

 

+44 207 260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)

James Black (Corporate Broking)



FTI Consulting

Simon Conway / Victoria Foster Mitchell

+44 203 727 1000

 
Notes to Editors:

hVIVO is an industry leading clinical development services business supporting product development for customers developing antivirals, vaccines and respiratory therapeutics.  Leveraging human disease models in human rhinovirus (HRV), RSV, Influenza (Flu) Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO platform illuminates the entire disease cycle in people from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted 56 clinical studies and inoculated over 2900 volunteers.